Genentech is set to present new, encouraging long-term follow-up data across a range of its key medicines at an upcoming medical conference. The data highlight the sustained impact and safety profiles of Polivy, Lunsumio, Columvi, and Hemlibra in treating various hematologic conditions. These findings could potentially reshape treatment paradigms for patients with lymphoma and hemophilia.
Polivy Demonstrates Prolonged Impact in DLBCL
Five-year analysis of the POLARIX study confirms the positive impact of Polivy (polatuzumab vedotin) plus rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) on outcomes in patients with diffuse large B-cell lymphoma (DLBCL). The study, which is an oral presentation, abstract #469, shows that the Polivy-based regimen continues to offer a significant benefit in this aggressive lymphoma subtype. Polivy is a first-in-class anti-CD79b antibody-drug conjugate (ADC).
Lunsumio Shows Durable Responses in Follicular Lymphoma
Data on Lunsumio (mosunetuzumab), a CD20xCD3 T-cell engaging bispecific antibody, demonstrates high rates of durable responses and a low rate of cytokine release syndrome (CRS) in patients with relapsed/refractory follicular lymphoma. The primary analysis of a pivotal Phase II study showed non-inferior exposure compared with intravenous administration. Furthermore, a four-year follow-up of a pivotal Phase II study (abstract #4407) indicates clinically meaningful outcomes in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies, including those with a history of POD24.
Columvi Maintains Durable Responses in LBCL
Fixed-duration glofitamab monotherapy continues to demonstrate durable responses in patients with relapsed or refractory large B-cell lymphoma, according to three-year follow-up data from a pivotal Phase II study (abstract #865). Additionally, glofitamab in combination with polatuzumab vedotin maintains durable responses and a manageable safety profile in patients with heavily pre-treated relapsed/refractory large B-cell lymphoma, including high-grade B-cell lymphoma, as shown in extended follow-up of a Phase Ib/II study (abstract #988).
Hemlibra Shows Effective Bleed Control in Infants with Hemophilia A
Exploratory analysis of the HAVEN 7 study (abstract #1214) reveals bleed patterns in infants, from birth to 12 months of age, with hemophilia A treated with emicizumab (Hemlibra). The data support the use of Hemlibra for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in this patient population.
These presentations underscore Genentech's commitment to advancing treatment options and improving outcomes for patients with hematologic malignancies and hemophilia.
